Efficacy of Rifaximin in patients with Irritable Bowel Syndrome and its comparison with previously used drugs : a retrospective and prospective study.

Slides:



Advertisements
Similar presentations
Diagnostic Work-up. There is no specific laboratory or imaging test to diagnose irritable bowel syndrome. Currently the diagnosis of IBS relies on meeting.
Advertisements

Contact Evaluation Your name Institution/organization Meeting Date International Standards 18, 19.
Irritable Bowel Syndrome Dr Bruce Davies Sept 2001Bruce Davies2 Introduction First described in % of patients present
1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Learning outcomes SGDs. Jaundice By the end of this discussion you should be able to; 1.Differentiate between Hepatocellular, Obstructive and hemolytic.
Overview of Irritable Bowel Syndrome
IRRITABLE BOWEL SYNDROME (IBS)
IBS Irritable Bowel syndrome Prince Sattam Bin AbdulAziz University College Of Pharmacy Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department.
Management of irritable bowel syndrome (IBS) WORKSHOP Dimitris Karanasios.
Irritable Bowel Syndrome Rahul Gladwin, MS3 University of Health Sciences Antigua School of Medicine rahul[AT]rahulgladwin.com.
Dalia Munoz.  Its an inflammatory bowel disease (IBD) that causes a long- lasting inflammation in your digestive tract.
C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.
Irritable Bowel Syndrome Ana Rodriguez. What is it? Irritable bowel syndrome is known as IBS it leads to abdominal pain in which includes pain and cramping.
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
Irritable Bowel Syndrome 1481 Nadeem Khan March 2, 2015.
Dr. Sengottuvel Viswanathan Delhi University Delhi.
TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.
Infants and Young Children and Pandemic H1N1 Influenza Key learning from seasonal flu and previous pandemics Children less than 5 years of age have increased.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
SLEEP DISORDERS IN ELDERLY RURAL POPULATION OF FASRALA (CENTRAL GREECE) Nikolaos Vaitsis 1, Matina Aggelakou-Vaitsi 1, Irene Anastassopoulou 2 1 Private.
Causes of Constipation. Main Point Constipation is a SYMPTOM Constipation is not a diagnosis.
COMORBIDITIES IN PATIENTS WITH IRRITABLE BOWEL SYNDROME Natalia Pritcan Alina Burianov,Gheata Irina Alina Burianov,Gheata Irina Doctor Melania Macarie.
THE IMPACT OF ANTI-DEPRESSANTS AND COGNITIVE THERAPY ON PANIC DISORDER Christopher Cannizzaro Rowan University Abnormal Psychology.
Corticosteroid dosing in the treatment of acute exacerbations of COPD Kurt A. Wargo, Pharm.D., BCPS, Takova D. Wallace, Pharm.D. Candidate 2014, Ryan E.
1 Ellora Islam Jodie Ly Tony Davi Sonaiya Kelley.
Incidence of hospitalisations in both groups Incidence of documented infections Abstract Problem statement: Patients on cancer chemotherapy are at substantial.
1 1 Zelnorm ® (tegaserod maleate) Advisory Committee Presentation Gastrointestinal Drugs July 14, 2004.
Treatment Arvin M. Aningalan. Treatment Options Patient counseling and dietary alterations Diarrhea – Stool-bulking agents – Antidiarrheal Agents – Serotonin.
Jackie Skradski Pharm.D. Candidate 2016 Ferris State University College of Pharmacy February 25, 2015.
1- Irritable Bowel Syndrome (IBS) 2- Constipation
Management of Irritable Bowel Syndrome (IBS) in Family Medicine Meera Kaur, PhD, RD, CDE Assistant Professor, Family Medicine University of Manitoba, Canada.
Afebrile Infants With UTI and the Risk for Bacteraemia Journal Club Sheffield Children’s Hospital Naheed Maher 7 th January 2015.
Vulvodynia Research Studies: National Institutes of Health.
Habit disorders Dr. Ibrahim Khasraw Lecturer in Pediatrics School of Medicine Sulaimani University of.
Are patients with chronic diseases a new challenge to general practice? Patients with irritable bowel syndrome in general practice Patients with irritable.
Sunil Kumar, B.K.Kapoor, Urvinderpal Singh, Vidhu Mittal Department of Pulmonary Medicine, GMC,Patiala PRESENTATION OF PULMONARY TUBERCULOSIS IN ELDERLY.
Efficacy of Topical Azithromycin & Cyclosporine A(CsA) vs CsA Alone in the Treatment of Dry Eyes Associated with Blepharitis Kenneth A. Beckman, M.D.,
FUNCTIONAL DİSEASE FUNCTIONAL DİSEASE Cengiz Pata, MD Gastroenterology Department,Yeditepe University Istanbul.
Learning About Drug Use1 An Overview of the Process of Changing Drug Use 1. EXAMINE Measure Existing Practices (Descriptive Quantitative Studies) 2. DIAGNOSE.
CLINICAL TRIALS – PHASE IV. PHASE IV  Phase IV are post marketing studies and provide basis for continued marketing. They may also provide information.
CLINICAL TIPS AND PEARLS. Clinical Tips and Pearls The most common type of chest pain is from myocardial infarction. The most common type of abdominal.
Dr. Nadira Mehriban. INTRODUCTION Diabetic retinopathy (DR) is one of the major micro vascular complications of diabetes and most significant cause of.
FODMAPs alter symptoms and the metabolome of patients with IBS : a randomised controlled trial Keith McIntosh, David E Reed, Theresa Schneider, Frances.
Case A 48 year old man presented with post prandial epigastric pain for 6 months. Omeprazole 20 mg/D is effective in relieving pain but pain recurs when.
A.Vogel Gastronol Gerda Crous SA Natural Products (Pty) Ltd.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
UVMHealth.org/MedCenter Functional dyspepsia (FD) is a common, disabling condition that affects up to 15% of the population [1]. However, our understanding.
Irritable Bowel Syndrome
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP
Seema Jain1, Rebecca Andridge2, Jessica Hellings3
Focus on Irritable Bowel Syndrome (IBS)
Predictive value of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and mean platelet volume for pelvic inflammatory disease Meryem Hocaoğlu.
Approach to patients with Diarrhea
IRRITABLE BOWEL SYNDROME
From: Postinfectious Irritable Bowel Syndrome
IBS-D -- From Diagnosis to Management
Incorporating New Therapies in IBS-C
Trap B and Hansen EH Euro Health Group, Denmark &
iPad Instructions iPad Instructions Polling Question.
Drugs for the treatment of irritable bowel syndrome (IBS)
CLINICAL SIGNIFICANCE AND
Implications for Practice
Diagnosis of irritable bowel syndrome
Rome IV: What Has Changed? Rome IV IBS Subtypes.
Clinical tips and pearls
ABSTRACT   Qualitative and Quantitative Assessment of the Essential Medicines List of Delhi State: A Time Series Analysis. Gupta U, Sangeeta S, Baishya.
Volume 151, Issue 6, Pages (December 2016)
Khai Hoan Tram, Jane O’Halloran, Rachel Presti, Jeffrey Atkinson
Presentation transcript:

Efficacy of Rifaximin in patients with Irritable Bowel Syndrome and its comparison with previously used drugs : a retrospective and prospective study. OMKAR SINGH Sachin Srivastav, Ashish Gautam, Mridul Chaturvedi, Dept of Medicine, S.N Medical College, Agra

AIMS AND OBJECTIVE- To evaluate the efficacy of Rifaximin at definite set points after therapy in patients with Irritable Bowel Syndrome (IBS) - Diarrhea predominant and its comparison with other commonly prescribed drugs. Study include those patients who have previously received various treatments including  Loperamide  Flouroquinilone+Metrogyl  Metrogyl  Psyllium Husk  Smooth Muscle Relaxants  Tricyclic Antidepressants  SSRIs  Probiotics  Prebiotics Patients were subjected to a detailed questionnaire regarding their satisfaction with various drugs. Rifaximin was started and their satisfaction level was recorded on 10 th, 40 th, 60 th,75 th,and 90 th day. Those patients who have not received any of the above drugs were prescribed the drug for 10 days and their level of satisfaction was noted

INCLUSION CRITERIA The ROME 3 Criteria for diagnosis of IBS-D, Patients attending the OPD having complaints suggestive of IBS-D and did not respond with oral anti amoebic and gut specific antibiotics, Patients previously labeled IBS- D after essential investigations and did not respond with previous treatment Between 20 to 50 years of age were included in the study. EXCLUSION CRITERIA Patient of IBS-C, IBS-M and IBS-U subtype Those who were taking Theophylline ATT, Narcotics, Alosetron, Lubiprostone, Warfarin,antipsychotics,antispasmodic, Antidiarrheal, Probiotics Any patient taking gut specific antibiotic or rifaximin patients With underlying co morbid conditions that can alter study results like diabetes mellitus, thyroid dysfunction, HIV, chronic kidney disease, chronic liver disease, abdominal tuberculosis and previous bowel resection or abdominal surgery (except cholecystectomy, appendectomy and pelvic organ surgery or cesarean section). Patients were subjected to a detailed questionnaire regarding their satisfaction with various drugs. Rifaximin was started and their satisfaction level was recorded on 10 th, 40 th, 60 th,75 th,and 90 th day. Total number of patients were 57 were inclluded in the study based on inclusion and exclusion criteria

Drugs Average satisfaction Rifaximin2.89 Loperamide2.24 Psyllium husk2.03 Smooth muscle relaxant 1.93 Tricyclic antidepressant 2 Ssris1.26 Probiotics1.57 Fq+metrogyl2.70 Metrogyl2.63 Prebiotics2.12. STUDY DAYS AVERAGE SATISFACTION with RIFAXIMIN

CONCLUSION Rifaximin----very effective drug for IBS in doveloped countries where recurrent infections are rare. However in developing countries like India where frequency of repeated infections due to poor hygenic conditions is high its efficacy is questioned We studied Rifaximin, one of the latest drug for the management of this disorder and compared it with drugs previously used. This study, a combination of retrospective as well as prospective showed that Rifaximin has the most satisfactory results in these patients and the average satisfaction level was also highest for Rifaximin, however the results were not sustained as with other drugs However further a second phase study is required to assess the effect of Rifaximin on repeating the therapy again and how frequently it should be repeated with a larger sample size. RIFAXIMIN EFFICACY BEST AMONG ALL DRUGS HOWEVER EFFECT NOT SUSTAINED MOST LIKELY DUE TO REPEATED INFECTION.